Recent developments in the diagnosis of drug-resistant tuberculosis

Mark P. Nicol, Helen Cox

Research output: Contribution to journalArticle

Abstract

Urgent steps are required to control the drug-resistant tuberculosis (TB) epidemic worldwide. Individualised treatment, using detailed drug-susceptibility test results to guide choice of antibiotics, improves patient outcomes and minimises adverse effects. Recent years have seen substantial advances in our ability to provide rapid, detailed drugresistanceprofilesusing genotypicmethodsfordetection of mutations conferring drug-resistance. Rapid testing using real-time PCR to target the most important drug-resistance mutations allows the diagnosis of drug resistance to be made with the first diagnostic test, even in low resource settings. The use of whole genome sequencing to infer resistance to a range of different drugs facilitates earlier tailoring of therapy and detection of resistant subpopulations in mixed infections. Low burden countries, such as Australia are well positioned to lead the development and refinement of these new methods, to accelerate the incorporation of thesenew toolsinto TB controlprograms inhigh burden countries.

Original languageEnglish
Pages (from-to)82-86
Number of pages5
JournalMicrobiology Australia
Volume40
Issue number2
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Multidrug-Resistant Tuberculosis
Drug Resistance
Mutation
Secondary Prevention
Coinfection
Routine Diagnostic Tests
Pharmaceutical Preparations
Real-Time Polymerase Chain Reaction
Tuberculosis
Genome
Anti-Bacterial Agents
Therapeutics

Cite this

@article{779e8c2b93bb44d888bb13df4652e818,
title = "Recent developments in the diagnosis of drug-resistant tuberculosis",
abstract = "Urgent steps are required to control the drug-resistant tuberculosis (TB) epidemic worldwide. Individualised treatment, using detailed drug-susceptibility test results to guide choice of antibiotics, improves patient outcomes and minimises adverse effects. Recent years have seen substantial advances in our ability to provide rapid, detailed drugresistanceprofilesusing genotypicmethodsfordetection of mutations conferring drug-resistance. Rapid testing using real-time PCR to target the most important drug-resistance mutations allows the diagnosis of drug resistance to be made with the first diagnostic test, even in low resource settings. The use of whole genome sequencing to infer resistance to a range of different drugs facilitates earlier tailoring of therapy and detection of resistant subpopulations in mixed infections. Low burden countries, such as Australia are well positioned to lead the development and refinement of these new methods, to accelerate the incorporation of thesenew toolsinto TB controlprograms inhigh burden countries.",
author = "Nicol, {Mark P.} and Helen Cox",
year = "2019",
month = "1",
day = "1",
doi = "10.1071/MA19023",
language = "English",
volume = "40",
pages = "82--86",
journal = "Microbiology Australia",
issn = "1324-4272",
publisher = "CSIRO Publishing",
number = "2",

}

Recent developments in the diagnosis of drug-resistant tuberculosis. / Nicol, Mark P.; Cox, Helen.

In: Microbiology Australia, Vol. 40, No. 2, 01.01.2019, p. 82-86.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recent developments in the diagnosis of drug-resistant tuberculosis

AU - Nicol, Mark P.

AU - Cox, Helen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Urgent steps are required to control the drug-resistant tuberculosis (TB) epidemic worldwide. Individualised treatment, using detailed drug-susceptibility test results to guide choice of antibiotics, improves patient outcomes and minimises adverse effects. Recent years have seen substantial advances in our ability to provide rapid, detailed drugresistanceprofilesusing genotypicmethodsfordetection of mutations conferring drug-resistance. Rapid testing using real-time PCR to target the most important drug-resistance mutations allows the diagnosis of drug resistance to be made with the first diagnostic test, even in low resource settings. The use of whole genome sequencing to infer resistance to a range of different drugs facilitates earlier tailoring of therapy and detection of resistant subpopulations in mixed infections. Low burden countries, such as Australia are well positioned to lead the development and refinement of these new methods, to accelerate the incorporation of thesenew toolsinto TB controlprograms inhigh burden countries.

AB - Urgent steps are required to control the drug-resistant tuberculosis (TB) epidemic worldwide. Individualised treatment, using detailed drug-susceptibility test results to guide choice of antibiotics, improves patient outcomes and minimises adverse effects. Recent years have seen substantial advances in our ability to provide rapid, detailed drugresistanceprofilesusing genotypicmethodsfordetection of mutations conferring drug-resistance. Rapid testing using real-time PCR to target the most important drug-resistance mutations allows the diagnosis of drug resistance to be made with the first diagnostic test, even in low resource settings. The use of whole genome sequencing to infer resistance to a range of different drugs facilitates earlier tailoring of therapy and detection of resistant subpopulations in mixed infections. Low burden countries, such as Australia are well positioned to lead the development and refinement of these new methods, to accelerate the incorporation of thesenew toolsinto TB controlprograms inhigh burden countries.

UR - http://www.scopus.com/inward/record.url?scp=85065320526&partnerID=8YFLogxK

U2 - 10.1071/MA19023

DO - 10.1071/MA19023

M3 - Article

VL - 40

SP - 82

EP - 86

JO - Microbiology Australia

JF - Microbiology Australia

SN - 1324-4272

IS - 2

ER -